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Addressing non-communicable diseases (“NCDs”) and their risk-factors is one of the most powerful ways of improving
longevity and healthy life expectancy for the foreseeable future – especially in low- and middle-income countries.
This paper reviews the role of law and governance reform in that process. We highlight the need for a comprehensive
approach that is grounded in the right to health and addresses three aspects: preventing NCDs and their risk factors,
improving access to NCD treatments, and addressing the social impacts of illness. We highlight some of the major
impediments to the passage and implementation of laws for the prevention and control of NCDs, and identify
important practical steps that governments can take as they consider legal and governance reforms at country level.
We review the emerging global architecture for NCDs, and emphasise the need for governance structures to harness
the energy of civil society organisations and to create a global movement that influences the policy agenda at the
country level. We also argue that the global monitoring framework would be more effective if it included key legal and
policy indicators. The paper identifies priorities for technical legal assistance in implementing the WHO Global Action
Plan for the Prevention and Control of NCDs 2013–2020. These include high-quality legal resources to assist countries to
evaluate reform options, investment in legal capacity building, and global leadership to respond to the likely increase in
requests by countries for technical legal assistance. We urge development agencies and other funders to recognise the
need for development assistance in these areas. Throughout the paper, we point to global experience in dealing with
HIV and draw out some relevant lessons for NCDs.Background
Nearly two out of every three deaths globally are caused by
chronic, non-communicable diseases (“NCDs”), including
cardiovascular disease, cancer, diabetes and chronic lung
diseases [1-3]. The modifiable causes of the leading NCDs
are well established: tobacco use, harmful use of alcohol,
obesity, lack of physical activity, and excess salt, sugar and
saturated fats in the diet [4-6]. About one quarter of global
NCD deaths occur before the age of 60, undermining pro-
ductivity and economic growth, especially in low- and
middle-income countries – where 80% of all deaths occur,
where deaths occur at a younger age, where safety nets are
fragile or absent, and where treatment costs are prohibitive
[4]. A study conducted for the World Economic Forum es-
timates that under a “business as usual” scenario, low- and
middle-income countries could lose $500 billion per year
over the period 2011–2025 due to NCD morbidity and* Correspondence: roger.magnusson@sydney.edu.au
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article, unless otherwise stated.mortality: roughly 4% of average GDP for these countries
[7]. Addressing NCDs and their risk factors is not merely a
priority for economic development: it is likely to be the
most powerful way of improving longevity and healthy life
expectancy for the foreseeable future – especially in low-
and middle-income countries.
Recognising these factors, in September 2011 the United
Nations General Assembly held a high-level meeting on
NCDs (“UNGA High-level Meeting”) [8]. In the lead-up
to this meeting, there was a significant level of agreement
about the low cost, cost-effective, feasible and evidence-
informed interventions that could most effectively reduce
the burden of NCDs in low- and middle-income countries
[4,5,7,9,10]. Summarised in Table 1, these priority inter-
ventions or “best buys” focus principally on tobacco cessa-
tion, moderating alcohol intake, improving diet, and
encouraging higher levels of physical activity. These prio-
rities have been reiterated in the WHO Action Plan for the
Prevention and Control of NCDs 2013–2020 [11] and else-
where in the literature [12,13]. Together, these measures
build on the WHO Framework Convention on TobaccooMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Prevention: legal and regulatory priorities for reducing major risk factors for non-communicable diseases
within the population [4]
Tobacco
Comprehensive implementation of the WHO Framework Convention on Tobacco Control (WHA56.1) especially:
● Imposing and increasing excise taxes on tobacco to reduce demand (FCTC Article 6) [BEST BUY];
● Smoking bans in public places, including workplaces, public transport, bars and restaurants (FCTC Article 8) [BEST BUY];
● Health warnings on tobacco products, and at point of sale; labelling controls (FCTC Article 11,12) [BEST BUY];
● Comprehensive bans on tobacco advertising, promotion and sponsorship, including in all media, in community settings,
and in retail establishments (FCTC Article 13) [BEST BUY];
● Bans on sales of tobacco to and by children, with monitoring and enforcement (FCTC Article 16);
● Penalties for smuggled and counterfeit tobacco; with adequate resources for monitoring and enforcement
(Article 15; protocol to eliminate illicit trade in tobacco products);
● Affordable treatment for tobacco dependence: supporting interventions for smoking cessation in primary care;
affordable pharmacological therapies (FCTC Article 14);
Alcohol
Implementation of the WHO Global Alcohol Strategy (A63/13), especially:
● Increasing excise taxes on alcoholic beverages (paras. 32–34) [BEST BUY];
● Penalties for smuggled and informal alcohol, with adequate resources for monitoring and enforcement (paras. 37–39);
● Restrictions on alcohol advertising and promotion through the media, in community settings and retail establishments;
restrictions on alcohol sponsorship of cultural and sporting events (paras. 29–31) [BEST BUY];
● Controls on access to retailed alcohol, including minimum age purchasing laws, licensing and other controls on hours
of retail sale, location and density of retail outlets (para. 27–28) [BEST BUY];
● Health warnings on alcohol products and at point of sale (paras. 19, 36);
● Drink-driving counter-measures, including random breath testing, a maximum 0.5 g/l blood alcohol concentration
(BAC) limit for adult drivers, with a reduced or zero limit for younger drivers (paras. 24–26);
Building on the WHO Global Strategy on Diet, Physical Activity and Health (WHA57.17):
● Institutional and governance reform to enable development of a comprehensive and multi-sectoral approach to policy
development for diet, nutrition and physical activity, with input from key sectors (agriculture, transport, education,
environmental and urban planning, sport, youth, industry, finance, and media and communications). City and local
governments should have a legal mandate to play a leading role (paras. 38–44);
Diet, and physical activity ● Measures to reduce salt levels in food, such as encouraging food reformulation through public reporting of
food manufacturers’ commitments to progressive reductions (para. 41); measures to replace saturated with
unsaturated fats in food products;
● Requiring food manufacturers to replace trans fats with polyunsaturated fats (para. 41) [4] [BEST BUY];
● Restrictions on marketing of foods and beverages high in salt, sugar and fats (especially to children): WHO, Set of
recommendations on marketing of foods and non-alcoholic beverages to children WHA 64.14, adopted May 2010);
● Improving food labelling to encourage healthier choices;
● Fiscal measures such as reduced taxation on healthier foods, and/or higher taxation for foods to be consumed
in lower quantities (para 41);
● Legislation to protect women’s right to breast-feed, without harassment or discrimination [4].
Other strategies ● Hepatitis B vaccination.
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Reduce the Harmful Use of Alcohol [15], the WHO Global
Strategy on Diet, Physical Activity and Health [16], and
other strategies [17,18]. Without substantial progress in
implementing these measures, countries are unlikely to
meet the global target of a 25% reduction in NCD mortality
by 2025 (“25 by 25”), adopted at the World Health Assem-
bly in May 2012 [19].
A striking feature of these priority interventions is their
reliance on legal and regulatory reforms. They are either fis-
cal policies (e.g. raising taxes), or their successful imple-
mentation will depend, in many cases, upon legislation or
subsidiary statutory instruments (regulations) that prescribestandards, mandate required actions and processes to be
followed, and require government agencies to play a cen-
tral role in monitoring and enforcement. This does not
mean, of course, legal and governance strategies are the
only strategies for controlling NCDs. A comprehensive ap-
proach to encouraging healthier lifestyles will also include
community-based programs, health promotion, and a
greater focus on prevention within primary care. Invest-
ment in health care systems – including infrastructure
and the health workforce – together with monitoring,
reporting and accountability mechanisms, and political
leadership at the highest level, are also critical elements
for successful national approaches [5].
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their way out” of the NCD crisis by investing in treatment
services alone will be futile unless matched by policies that
target the whole population, address the shared risk fac-
tors for the leading NCDs, and empower individuals and
communities to lead healthier lives [9]. Prevention is vital
to the control of NCDs, and law is an important tool for
achieving this goal.
This paper reviews the role of law and governance reform
in the implementation of successful national responses to
NCDs, particularly in low- and middle-income countries.
We highlight the need for governments, NGOs, develop-
ment agencies and other stakeholders to recognise the im-
portance of law in strategies for both prevention and
treatment of NCDs, and to plan for greater investment in
legal capacity-building in low- and middle-income coun-
tries. While there is considerable agreement about legisla-
tive priorities for prevention, law’s role in improving access
to treatment for NCDs is more variable and country-
specific, but relates closely to the challenge of strengthening
primary health care systems. In addition, we highlight the
role of law in addressing the social impact of illness, inclu-
ding its role in preventing discrimination against people
with diabetes and other NCDs [20]. Given that the leading
NCDs share a cluster of inter-related yet modifiable risk
factors, there are benefits in adopting a national strategy
that requires countries to set out their responses to all the
major risk factors. By focusing on the leading NCDs and
their risk factors generally, it is less likely that major risk
factors will be ignored. At the same time, countries will still
need to make choices about priorities [21], and it may be
important to protect the work already undertaken at
ational level in specific areas, such as tobacco control.
Action on all three fronts – prevention of key risk fac-
tors, treatment for NCDs, and addressing the social im-
pacts of illness – makes sense in policy terms by reducing
future expenditures, improving productivity, and reducing
suffering. In addition, however, taking actions on these
fronts is part of the obligation that many countries have
undertaken to respect, protect and fulfil the right to
health. First recognized in the Constitution of the World
Health Organization [22], the right to health is enshrined
in six core international human rights treaties including
the International Covenant on Economic, Social and Cul-
tural Rights (“ICESCR”) [23]. It is also recognised in three
regional human rights agreements [24-26], and in national
constitutions in some countries, such as Brazil [27].
Having identified priorities for NCD-related law reform,
this paper points to some of the most difficult challenges
that governments face when using legal strategies to pre-
vent and manage NCDs. We identify key practical steps
that governments can take as they consider law and go-
vernance reforms at country level. Finally, we consider
global architecture for NCDs, accountability for law andgovernance reforms, and priorities for global leadership in
NCD-related law and governance reform in future.
There is a great deal to be learned from 30 years of ex-
perience in responding to HIV in developing countries
[28]. The leading NCDs have important similarities with
HIV, including the fact that both are transmitted through
human behaviours that are modifiable, yet largely deter-
mined by cultural, social and economic factors. HIV and
NCDs both impact heavily on people during their pro-
ductive years, both require an inter-sectoral response from
government that addresses both prevention and treat-
ment, and both depend on an enabling legal environment.
As with HIV, the burden of caring is more likely to fall on
women, who also become the sole breadwinner when a
male partner falls ill. Without adequate national or private
health insurance, treatment costs may rapidly deplete
household savings, pushing families into poverty and for-
cing children, particularly girls, to quit school [29,30].
Throughout the paper, we draw attention to how the
global governance of HIV might inform law reform and
governance processes for NCDs.
Law reform priorities for the control of NCDs:
balancing prevention and treatment
Low- and middle-income countries looking to respond
to the rising burden of cardiovascular disease, diabetes
and tobacco-related diseases are confronted by many
challenges. One of the most immediate is to balance in-
vestments in the delivery of healthcare services to those
who are already sick with attention to the preventive
policies that will largely benefit future generations. The
scope and scale of public health law reform for NCDs in
each country will reflect the balance that is struck
between prevention, and treatment.
The case for prevention is based on the fact that the ris-
ing burden of NCDs in low- and middle-income countries
is mostly attributable to shared risk factors that are modi-
fiable through public policies that target the population
generally, as well as high-risk individuals [9]. Although es-
timates vary, over 2.6 million of the 7.6 million annual
cancer deaths [31] and, theoretically, all tobacco-related
deaths, could be avoided through the implementation of
preventive policies targeting known risk factors. The case
for prevention also depends, implicitly, on the conse-
quences of inaction. For example, the number of adults
with diabetes is expected to rise from 285 million to 439
million between 2010 and 2030, with a 69% increase in
developing countries [32]. Taking preventive action now is
vital to the capacity of countries to afford the costs of
treatment for their populations in future.
Affordable and cost-effective policies for reducing NCD
risk factors are available and have been described, inclu-
ding salt reduction [5,7,33-35] and implementing coun-
tries’ obligations under the FCTC [14]. For example,
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mostly population-level preventive policies in six middle-
income countries could be implemented at a cost of US
$1.5-4.5 per person [35]. This is a cost of less than 1% of
total per capita health spending within countries including
China, Mexico, Brazil and Russia [9]. At US$11.4 billion
per year, the total cost of a set of “best buy” interventions
for prevention and treatment looks relatively modest in the
sense that it amounts to an investment of less than US$1
per person per year in low-income countries, less than US
$1.50 in lower middle-income countries, and US$3 in
upper middle-income countries [33]. The overwhelming
majority of these costs are made up of screening and drug
treatment costs for high-risk individuals, rather than the less
expensive, population-based, preventive interventions that
focus on reducing tobacco use and harmful use of alcohol,
improving diet, and encouraging physical activity [33].
Although it makes little sense for governments to invest
almost exclusively in treating illness when affordable po-
licies are available to reduce the scale of treatment costs in
future, the tendency for prevention to languish in national
budgets is well recognised. The costs of neglecting preven-
tion can be deferred – at least temporarily. There may also
be more immediate political pressures to respond to pa-
tients who are sick now, and these costs alone may outstrip
limited budgets. An additional factor is that prevention can-
not be achieved simply by spending more. Table 1 summa-
rizes the World Health Organization (“WHO”)’s priority
recommendations for NCD prevention, including “best
buys”. In order to implement these recommendations,
governments must deal with coordinated campaigns from
industry lobby groups (tobacco, alcohol and food manufac-
turers and retailers), and risk challenges from trading part-
ners appealing to World Trade Organization (“WTO”)
agreements, regional trade agreements, and bilateral in-
vestment treaties (“BITs”) [36-38]. Population-wide pre-
ventive policies cannot easily be implemented without
national political leadership at the highest level, since
these policies relate to a range of non-health sectors
and must be implemented by non-health Ministries. For
these reasons, effective NCD prevention requires a
multi-sectoral, “all-of-government” approach, ideally led
by a President or Prime Minister [39-42]. The creation of
new national structures requires considerable political ef-
fort and broad political support: this is why, in our view,
accountability mechanisms for NCDs need to monitor ac-
tions taken at the national level to implement specific legal
and policy measures, in addition to monitoring national
trends in risk factors and disease outcomes.
NCDs raise similar challenges to the HIV epidemic: pre-
vention calls for significant changes in the behaviour of
populations, and in the case of some NCDs, requires the
provision of lifelong access to essential medicines. An im-
portant lesson learned from HIV programs, however, wasthat a two-pronged approach that integrates treatment
and prevention is superior to an approach that prioritises
prevention alone [43]. There are several reasons for this.
People living with HIV have long been powerful advocates
for policy and law reform [44]. The lifestyle and behav-
ioural changes that are required to prevent transmission
benefit from peer education and personal testimony from
persons infected. Drug treatment for HIV has also been
shown to prevent new infections as well as delay disease
progression [45]. In societies where the treatment needs of
those with HIV – and NCDs – are acknowledged and
resourced, prevention is more likely to be effective. In so-
cieties where there is no realistic prospect of treatment,
there is no evidence to suggest that individuals are more
likely to adopt the behaviours that will prevent them from
falling sick. Another lesson from HIV is the importance of
considering gender in policies aimed at prevention and
treatment. For example, cultural restrictions may limit
girls’ access to sporting facilities, or create invisible bar-
riers to a physically active lifestyle. Further, in some cul-
tures, women and girls’ diets are poorer than their male
counterparts, even within the same household [46-48].
An effective response to NCDs requires governments to
adopt cost-effective and mutually reinforcing measures for
both prevention and treatment [4,5,10], while also ad-
dressing discrimination and the social impacts of illness.
Treatment is prevention in the case of life-long, chronic
conditions and risk-factors that – like obesity, hyperten-
sion, high cholesterol and diabetes – frequently deteriorate
further without appropriate management. Firstly, the pri-
mary health care system is a critical setting for individual-
focused prevention and for reducing future healthcare
costs. Secondly, preventive strategies at the population
level can help to conserve resources, in both the short and
longer term. For example, studies of the implementation
of smoke-free laws illustrate that prevention can signifi-
cantly reduce hospital admissions [49-51], due to the im-
pact of tobacco smoke as a risk-factor for coronary heart
disease [52]. Smoking bans may reduce rates of premature
birth, and pediatric hospital admissions for asthma, by ap-
proximately 10 percent [53]. Priority interventions for pre-
vention, including raising taxes on tobacco and alcohol
products, and sugary drinks, can moderate demand for
these products, while also raising the additional revenues
required to fund universal access to health services, inclu-
ding priority treatments and essential drugs for NCDs [54].
Improving access to NCD treatments: legal and
regulatory priorities
While there is a measure of agreement about the prior-
ities for preventing NCDs and reducing their risk factors
(Table 1), there is no similar consensus when it comes to
the legal and governance reforms that are necessary to
improve access to NCD treatments. An initial point to
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intended to improve access to NCD treatments will also
benefit the health system generally; unlike the priorities
for NCD prevention, priorities for improving treatment of
the leading NCDs are unlikely to be specific to NCDs.
In our view, the legal and governance priorities for im-
proving access to NCD treatment are grounded in human
rights law [55,56]. For example, the right to health, as
recognised in Article 12 of the ICESCR [23], requires coun-
tries to take progressive, concrete steps towards ensuring
the availability and accessibility of quality public health and
health care services, and essential drugs, especially for so-
cially disadvantaged and marginalised groups that are vul-
nerable to exclusion from existing services [55]. Countries
have an immediate obligation to take steps towards the full
realisation of the right to health, including through legisla-
tive, administrative and budgetary measures. Article 14 of
the Framework Convention on Tobacco Control also recog-
nises the importance of treatment, imposing obligations on
signatory countries to take effective measures to “promote
cessation of tobacco use and adequate treatment for to-
bacco dependence” [14].
Cost-effective interventions for the primary prevention
and treatment of NCDs that have been identified include
multi-drug regimes for treating hypertension, glycaemic
control for diabetes, and screening for cervical cancer
[4,34,57,58]. On the other hand, rates of use of proven sec-
ondary prevention drugs remain shockingly low. Yusuf and
colleagues found that 58% of those with coronary heart dis-
ease, and 50% of those with stroke, received none of four
effective drugs for secondary prevention. In low-income
countries, 83% lacked access [59]. Although people with
NCDs frequently require a combination of drugs, in many
low- and middle-income countries the cost of accessing
these drugs pushes large segments of the population into
poverty [60-62].
As noted above, improving access to cost-effective treat-
ments for NCDs cannot be considered in isolation, but de-
pends on improvements in the overall functioning of
national health systems [4,57,63,64]. While there is no uni-
versally applicable model for reform, law and governance
play an important role in strengthening the components of
the primary health care system. Major components include:
 financing mechanisms for the provision of health
services;
 the training, development and retention of the
health workforce;
 strategies for achieving universal access to essential
medicines, vaccines and technology;
 the development of an effective health information
system;
 the management of infrastructure and capital
investments; mechanisms for governance and accountability, and
 high-level leadership [65].
In Table 2, we have proposed a set of legal and regula-
tory priorities that countries may need to address in the
course of strengthening their health systems to provide for
universal access to (and financing for) essential health ser-
vices and medicines, to improve the training and retention
of the health workforce, and to improve national health in-
formation systems. These reforms cover a wide area.
Below, we focus more specifically on law’s role in support-
ing access to essential health care services and medicines.
Legal recognition of the right of all members of the
population to access essential health services, vaccinations,
essential medicines and technologies – at prices they can
afford – provides an important foundation for health re-
source allocation and planning by governments. Recogni-
tion of such a right would not require government to
become the sole provider of these services. However, it
would commit government to pursuing those intermediate
objectives that will help to achieve the broader goal of uni-
versal health coverage. These intermediate objectives in-
clude: improving financial protection, improving the
quality of services, and reducing the gap between the need
for services and the use of those services [66].
Around two-thirds of countries have constitutions that
recognize a right to health or to healthcare services [67]. In
countries where this right is enforceable through the courts,
it may provide a pathway for disadvantaged and vulnerable
groups to challenge the denial of basic health rights. In
Colombia, the Ministry of Social Protection initiated a
sweeping reform of its health system – including changes
in the coverage of health care services – following a finding
by the Constitutional Court that systemic problems with
the public health system constituted failure to fulfil the
right to health [68]. Venezuela and Peru have also adjusted
public health spending following court rulings [69,70].
Constitutional recognition of the right to health pro-
vides a legal basis for advocacy on behalf of vulnerable
and disadvantaged groups who have been excluded from
health services and from other resources for a healthy life,
due to problems with cost, poor service quality, the phys-
ical location of services, and discrimination. In some cases,
the constitutional right has also been recognised in legisla-
tion. For example, South Africa’s National Health Act pro-
vides legislative recognition of a range of health-related
rights, including a commitment to progressively realise
the right to health care that also appears in the constitu-
tion (Appendix A). However, even in countries where
there is no constitutional right to access health services,
legislative recognition of the right to health and of the
state’s commitment to improving access to health services
provides an important platform for advancing the interests
of vulnerable populations.
Table 2 Treatment: some proposed legal and regulatory priorities for improving access to treatment for the leading NCDs
Universal access to essential health
services and medicines
● Formal legal recognition of the right of all members of the population to access a minimum basket
of essential health care services, essential drugs, and essential technologies, at prices they can afford,
on basis of medical need. This legal entitlement provides a foundation for planning and budgeting
by governments, and a legal pathway for disadvantaged groups to challenge discrimination and
the denial of basic health rights.
● Protection from discrimination in access to health services: under the ICESCR, countries have an
immediate obligation to respect the right to health by preventing discrimination in access to curative,
palliative and preventive health services. To protect vulnerable individuals and groups from being excluded,
complaints mechanisms should exist for investigating and remedying discriminatory practices, on grounds
including: race, colour, caste or social status, sex, language, religious or political opinion, national origin,
physical or mental disability, health status (including HIV status) and sexual orientation.
Health financing for the provision
of health care services
● Effective implementation of the right to access essential health services will require governments
to formally define the parameters of safety nets and health care entitlements under publicly provided
and publicly subsidised schemes.
● Governments should develop a national list of essential medicines and technologies that are
available in primary health care centres and/or district hospitals. Governments can use their
power as purchaser or subsidiser of medicines to negotiate lower prices.
● Governments should also consider establishing a national procurement authority with responsibility
for monitoring prices, encouraging the use of generics, reducing waste and inappropriate
prescribing practices, and reducing duties, taxes and other mark-ups on essential drugs.
● Governments should ensure that national patent laws authorise the use of the flexibilities
recognised in the Agreement on Trade Related Aspects of Intellectual Property (“TRIPS”),
and avoid entering bilateral agreements that exclude their right to use these flexibilities.
● Governments should consider establishing a competition regulator to encourage competition
and enforce competition laws in the health sector, in order to reduce overall costs,
and to fight corruption and collusion.
Training and retention of
the health workforce
● The compulsory licensing of medical and allied health professionals enables authorities to
prescribe the training and qualifications required for practice, to prescribe ongoing professional
training, to monitor quality and to improve accountability. The administering agency or
body may also investigate complaints and impose conditions on practice.
● Governments should investigate performance-based payment systems to encourage
community-based healthcare clinics and posts to reach out to local communities,
and to follow-up and manage health risks within their population.
● Laws authorizing non-physician prescribing could increase access to drugs for chronic conditions
and improve pain relief.
● All countries should implement the WHO Global Code of Practice on International Recruitment
of Health Personnel (2010). Countries suffering high levels of migration of domestically-trained
health care workers may consider worker retention strategies, including compulsory
service requirements and financial incentives.
Development of an effective
health information system
● Building on a system for registration of all births and deaths, countries should implement
compulsory reporting requirements for designated communicable diseases and privacy
protection for health information and medical records.
● Legislation may create a mandate for the collection and protection of a minimum national
data set (comprising census data, civil registration data, notifiable diseases data, household
survey data and medical records data) administered by a health information authority.
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services and essential medicines needs to be imple-
mented through government policies, programs and
budgets. This depends upon several things. Firstly, go-
vernments will need to define individuals’ entitlements
by formally stating the parameters of government safety
nets and program entitlements, including any means-
tested co-payments (contributions by individuals to the
costs of their care), and right-of-access to publicly-
funded services for those who cannot afford to pay. Pre-
payment mechanisms, such as taxation or compulsory
insurance contributions, are most effective as forms of
financing and will be an indispensable part of thestrategy for any country committed to fulfilling the right
to health [54]. Subsidies are a feature of all financially
stable financing systems that aim to provide universal
coverage and to avoid imposing catastrophic financial
burdens on individuals when illness strikes. Subsidies
may be paid by governments, employers, by insured
persons on higher incomes, or frequently a combination
of these. The WHO has recommended that govern-
ments increase the public funds that are available for
health financing by improving revenue collection, and
prioritising national budgets so that at least 15% is ap-
propriated to health [54]. Law can support these po-
licies by eliminating some of the indirect barriers to
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ing a worker’s entitlement to a minimum number of
paid days off work due to illness.
Secondly, to improve access to health services, govern-
ments need to ensure that individuals are protected from
discrimination, both in their access to health services, and
in the quality, appropriateness and timely delivery of those
services. Under the ICESCR, countries have an immediate
obligation to respect the right to health by preventing dis-
crimination in access to curative, palliative and preventive
services [55]. Although HIV-related stigma and discrimin-
ation are well recognised, obesity, diabetes, alcoholism, and
increasingly, tobacco use and nicotine addiction are also
stigmatised in different contexts (including in the context
of healthcare provision) [71]. The 2011 Global Diabetes
Plan of the International Diabetes Federation includes stop-
ping discrimination as one of its three objectives, along
with prevention and treatment of diabetes [20]. All three
goals are closely linked. For example, in northern India,
there are dramatic differences in rates of diagnosis and in
the level of management of Type 1 diabetes in girls, as
compared to boys, due to gender-based discrimination and
the stigma associated with Type 1 diabetes, particularly
among girls [72].
Regardless of whether protection from discrimination is
a constitutional right, or is reflected in legislation, effective
protection requires individuals and advocacy groups to
have access to the courts or to other agencies that have
both a legal mandate to investigate complaints, and the
power to make determinations that bind service providers.
Thirdly, providing universal access to essential medi-
cines at affordable prices is a necessary component of pro-
viding universal access to health care services for NCDs
and other diseases [57]. The WHO has encouraged coun-
tries to amend their national legislation to formalise this
right [73]. According to the WHO, three of the ten leading
causes of inefficiency in health systems relate to medi-
cines. These include the underuse of generics, the use of
substandard and counterfeit medicines, and inappropriate
and ineffective use of medicines [54]. In low- and middle-
income countries, medicines are estimated to account for
in excess of 20-30% of health spending [54]. In view of the
anticipated increased demand for NCD treatments, the
need to deal with these leakages, including through regula-
tion, will become even more urgent.
By itself, legislation is not a solution for weak health sys-
tems, including the problems caused by under-budgeting,
poor demand forecasting, ineffective procurement and
poor distribution systems. However, governance reform
can help to provide the structures and principles for im-
proving access; for example, by extending government-
funded insurance schemes to include reimbursement for
essential medicines (thereby reducing the largest compo-
nent of out-of-pocket household health expenditures), andby requiring the use of generic medicines, where suitable,
in policies for public procurement of essential medicines
[74]. Priorities for reducing the overall cost of essential
medicines include exempting medicines from import du-
ties and value added taxes, prescribing maximum mark-
ups in the supply chain, and encouraging prescribers to
use generics. Countries may also wish to consider the ben-
efits of establishing a non-departmental agency with a
mandate to establish a national list of essential medicines,
together with guidelines for their rational use, and to
monitor both the demand for these medicines and prices
paid. We have proposed a number of additional potential
regulatory functions of a national medicines administra-
tion (Appendix B).
The WTO Agreement on Trade-Related Aspects of Intel-
lectual Property Rights (“TRIPS”) recognises a range of
strategies (“flexibilities”) to permit countries to achieve ac-
cess to generic formulations of medicines patented under
law [75]. In order to take advantage of these, countries may
wish to ensure that their domestic patent laws authorise
the full use of TRIPS flexibilities, including the issuing of
compulsory licenses and parallel importation [76-79].
National governments should be wary of surrendering
TRIPS rights and flexibilities in free trade agreements, and
of passing domestic legislation granting more generous
patent protections on pharmaceuticals than TRIPS requires.
In the Political Declaration of the UNGA High-level
Meeting, UN members committed to “comprehensive and
cost-effective prevention, treatment and care for the inte-
grated management of non-communicable diseases”,
including “increased access to affordable, safe, effective
and quality medicines and diagnostics”, and full use of
TRIPS flexibilities [80]. Despite this rhetoric, trade dis-
putes over access to NCD drugs are likely to increase,
given the reality that US and European multinational drug
companies have invested heavily in drugs for chronic con-
ditions and see “emerging markets” (i.e. countries such as
India, China and Brazil) as growth areas [81,82]. Pooled
procurement and other access strategies will be required
to improve access to drugs that remain unavailable at
affordable prices in many countries [81]. An important
impediment to treatment is that pharmaceutical compa-
nies price their drugs differently on a country-by-country
basis, rather than by the capacity of the patient, or health
insurer, to pay. In countries that have a substantial and
growing middle class, drug companies are unlikely to want
to negotiate on price – yet the majority of the world’s poor
now live in middle-income countries [83].
Provision of adequate pain relief and palliative care is an
important priority in the treatment of NCDs, yet the
WHO estimates that approximately 80% of the global
population live in countries without access to morphine
for pain relief [84]. The right to adequate pain relief is im-
plied within the right to health [85,86]. Support is growing
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to establish laws and policies to promote access to fully
adequate pain management [87]. Priorities for countries
include eliminating regulations that create direct or
indirect obstacles to the prescription, possession and
administration of opioids (including morphine) for the
purposes of pain management and palliative care, in ac-
cordance with clinical need and standards of profes-
sional practice [84,88].
Challenges to the effective use of law in response
to NCDs
To summarise so far: there is a well-defined set of “best
buys” for preventing NCDs at the population level. Many
of these interventions rely on legislation and regulatory
changes for implementation (Table 1). Law also has an im-
portant role in strengthening healthcare systems in low-
and middle-income countries in order to improve NCD
treatment (Table 2). A related challenge is addressing the
social impact of illness for those with NCDs: this includes
providing legal protection from discrimination, and effec-
tive disability support. Law reform in these areas presents
a formidable challenge. Progress is likely to lag behind
expectations, even in clearly defined areas such as imple-
mentation of the FCTC. For example, WHO reported in
2013 that one third of the world’s population, or 2.3 billion
people, were now covered by at least one tobacco control
measure recommended by the FCTC, such as warning la-
bels, smoke-free environmental controls, tobacco taxes or
tobacco advertising bans. However, only 1 billion people
were covered by two or more such measures [89]. Four
challenges stand out.
Firstly, although cost-effective interventions for preven-
tion and treatment do exist, demands for funding them –
to the tune of $11.4 billion per year, mostly for treatment
[34] – have come during a sustained global economic
downturn. Funding on this scale is unlikely to materialise
[90]. Delivering treatment reliably and equitably depends
on strengthening primary healthcare systems. Progress
tends to be slow, partly because of the need for investment
in all elements of the system (financing mechanisms,
essential medicines, health workforce, and so on), and for
effective integration between them. In many low- and
middle-income countries, structures and programs have
already been established for the provision of HIV-related
treatment. Given the similarities between HIV and NCDs –
including the need for continuity of care in an environment
of health system constraints – building on these existing
structures may, particularly in countries with severely li-
mited resources, provide the most effective way of meeting
growing demand for NCD services [28,91].
Secondly, NCDs are exacerbated by the global market-
ing of tobacco, alcohol and unhealthy food [92,93]. Despite
their differences, tobacco, alcohol and food manufacturersand retailers all share an economic interest in expanding
markets for the risk factors that are driving the global
epidemic of NCDs [94-97]. Each of the evidence-based,
cost-effective measures summarised in Table 1 represent a
potential threat to revenues. As such, industry organisations
will perceive them as a business risk and will seek to
manage them through political lobbying, legal manoeuvres,
pre-emptive self-regulatory schemes, corporate social
responsibility initiatives, stakeholder marketing [98], adver-
tising, and other strategies for shaping favourable commu-
nity perceptions. In debates about business regulation,
rhetoric plays a huge part. For example, it is highly ironic
that even as multinational tobacco companies rush to ex-
ploit huge markets and weak tobacco controls in develop-
ing countries, evidence-based international standards such
as the FCTC are framed, by some, as an instrument of
neo-colonialism that threatens national sovereignty [99].
To a significant degree, progress will depend on the cap-
acity and willingness of governments – spurred on by civil
society organisations – to regulate the business sector.
The role of civil society deserves special emphasis. The
capacity for full engagement by civil society requires respect
for freedom of speech and freedom of association. Patients’
rights groups, medical and public health associations, orga-
nisations promoting the rights of women, children and dis-
abled people, and legal and human rights organisations
must have the freedom to advocate for the government
actions that are necessary to address NCDs.
The influence of industry lobbyists is only one reason
why governments may be reluctant to introduce priority in-
terventions for NCDs. Other reasons include the relatively
muted demand for these measures in countries where a
large proportion of the population has low levels of educa-
tion, and the reluctance of governments to adopt measures
that could be perceived as creating a less favourable envi-
ronment for foreign investment. In addition, in many coun-
tries, public health laws are outdated, technical capacity is
lacking, the rule of law is weak, conflicts of interest are
common, and corruption is part of the political reality.
National governments must also navigate WTO rules and
obligations under multilateral agreements and (“BITs”),
while resisting pressure from high-income countries –
including their own development partners – whose domi-
ciled companies benefit from global trade and investment
in tobacco, alcohol and unhealthy food [36-38,100,101].
Innovator governments are likely to be singled out for
special treatment, as illustrated by the BIT dispute
between Philip Morris and Uruguay over the latter’s pro-
posed tobacco health warning legislation [102], and the
suite of challenges to Australia’s legislation requiring plain
packaging of tobacco products [103]. Within this challen-
ging environment, the implementation of effective mea-
sures to reduce risk factors for NCDs is more difficult
than many assume.
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the implementation of preventive measures appeals to lib-
ertarian values and to the rhetorical force of concepts such
as “personal responsibility” and distaste for a “nanny state”
[104-111]. Nevertheless, the priority recommendations set
out in Table 1 involve little interference with the freedom
of adults to make their own choices, with the exception of
smoke-free laws and drink-driving controls, which also
aim to prevent harm to others. Rather, these interventions
constrain the for-profit activities of manufacturers and
retailers whose products make a significant contribution
to the burden of disease. It is true that taxes increase the
cost of choosing unhealthy products, and that advertising
controls moderate exposure to marketing of unhealthy
products [97]. Yet, governments have a legal obligation, as
stewards of the health of their populations, to create con-
ditions for the realisation of the highest attainable stan-
dard of health [55]. Governments should not abandon this
responsibility to private markets.
A final challenge worth noting, as Table 1 illustrates, is
that since NCDs are attributable to a wide range of risk
factors, an effective response will likely rest on the com-
bined impact of a variety of interventions, each of which is
likely to face vigorous resistance from industry. Reducing
tobacco use, for example, requires at a minimum that
countries raise excise taxes, eliminate smoking in public
places, impose health warnings and point-of-sale controls,
and comprehensively ban the advertising, promotion and
sponsoring of tobacco products. Rapid implementation of
the full set of interventions may be difficult to achieve:
reform of public health laws tends to be incremental.
Three important practical considerations follow from
these obstacles to the implementation of effective laws
and policies for NCD prevention and treatment. First, pro-
gress requires high-level leadership by national political
figures. Presidents, Prime Ministers and senior cabinet
members need to become personally involved: their lead-
ership should be directed towards framing NCDs as an
obstacle to national economic and social development,
and to fostering an inter-sectoral, government-wide re-
sponse [41]. Secondly, NCDs call for an all-of-government
response not only because many of the priority interven-
tions will be implemented outside of the health sector, but
also because broadly-based political support will be
needed to secure passage of the necessary laws and bud-
gets. In some countries, existing multi-sectoral structures
for coordinating a national response to HIV may be
appropriate for adapting to NCDs [91].
Thirdly, governments should focus their initial efforts
and budgets on those measures that will yield the greatest
results in terms of reducing death and disability. Countries
with high rates of tobacco use cannot hope to make sig-
nificant progress in reducing NCDs until they make to-
bacco control a priority [112,113]. Countries that have notyet signed the FCTC should do so urgently: this includes
high-population countries such as Indonesia, where 61%
of males are current smokers and where smoking rates for
boys aged 15–19 doubled from 14% to 33% between 1995
and 2004 [114,115].
Within the area of tobacco control, the WHO’s MPO-
WER package selects six priority areas for policy action
from the FCTC and explains their rationale and evidence
base [116]. One study estimates that if MPOWER po-
licies had been implemented globally in 2010, smoking
rates would have fallen to 13.2% by 2030 (523 million
smokers), instead of the 22% (872 million smokers) esti-
mated on current trends [117]. The Lancet NCD Action
group has argued that countries with limited human and fi-
nancial resources should prioritise two highly cost-effective
population-wide strategies (tobacco control, and dietary salt
reduction), and one individual-based strategy (treatment of
individuals at high risk for CVD or who have had a heart
attack or stroke) [21,118]. Once these interventions are in
place, countries should expand their response as resources
permit to include other cost-effective interventions, particu-
larly those identified in Table 1. The good news is that go-
vernments implementing these priority measures can
expect rapid – rather than gradual – reductions in morta-
lity, particularly from cardiovascular disease [119].
Establishing a national legislative and governance
framework for NCDs
There is a growing literature that aims to assist countries
to identify policy priorities for NCDs and to make best use
of limited resources [4,5,10,12,13,21,120-122]. Not all pri-
orities require legislation, and the mechanism for imple-
menting priority measures will vary from country to
country. Relevant pathways for implementation include
the direct use of Presidential powers, legislation passed by
Parliament, and regulations issued by executive agencies
exercising delegated powers under relevant codes or sta-
tutes. Two important variables that are relevant to imple-
mentation are the constitutional structure and division of
legislative powers between national and regional par-
liaments; and secondly, the presence or absence of explicitly-
recognised fundamental rights and freedoms within federal
and state constitutions.
In countries that have a federal structure, legislative
powers will be shared between national and state (i.e. re-
gional) governments, and each will have defined responsi-
bilities. Each government will also have its own budget,
and sources of revenue. National laws, effectively enforced,
have the power to improve the health of the entire coun-
try, although their passage may be more difficult to
achieve in political terms. On the other hand, provided
there is adequate political leadership, state and local go-
vernments may have considerable flexibility to experiment
with innovative approaches that have not yet achieved
Magnusson and Patterson Globalization and Health 2014, 10:44 Page 10 of 18
http://www.globalizationandhealth.com/content/10/1/44widespread political support, and to build the evidence
base for effective public health law [123]. Where appropri-
ate, public health advocates should encourage “competi-
tive federalism”, by encouraging regional and city leaders
to implement best practice, and to be national and inter-
national leaders in health policies.
National constitutions provide both constraints and op-
portunities for implementing priorities for the control of
NCDs. In the United States, for example, the First Amend-
ment to the Constitution constrains the capacity of legisla-
tures to pass legislation prohibiting or limiting the truthful
advertising of tobacco and alcohol products to adults
[124,125]. First Amendment jurisprudence suggests that it
will be very difficult for public health laws forbidding retail
advertising, suppressing tobacco trademarks or other dis-
tinguishing brand features, or imposing mandatory warn-
ings on products, to pass constitutional scrutiny in the
absence of a substantial body of evidence demonstrating
the independent impact of each one of these laws in redu-
cing smoking rates or other harmful exposures. Countries
that prioritise freedom of speech over other public interests
are likely to be followers, rather than leaders, when it comes
to laws that seek to re-balance the informational environ-
ment in favour of public health [126,127].
On the other hand, in countries whose constitutions give
individuals a right to challenge laws that infringe constitu-
tionally protected rights, or to challenge the failure of gov-
ernments to fulfil or protect those rights, there are
opportunities for litigants to seek protection from harmful
exposures and for access to other determinants of a healthy
life [128]. In one well-known example, the Supreme Court
of India held that smoking in a range of public places brea-
ched the constitutional right to protection of life and per-
sonal liberty [129]. The Court called upon federal and state
governments to pass legislation prohibiting smoking in a
range of public settings. These restrictions were included in
subsequent federal tobacco control legislation passed in
2003 [130]. This example also illustrates the importance of
litigation as a strategy for responding to industries that
promote harmful products [14,131].
In this section, we highlight two important steps in the
practical process of establishing legislative and governance
frameworks for a national response to NCDs. The first
step is to review current laws, policies and programs in
order to assess the state of progress, and to map where re-
sponsibility lies for these functions within government. In
some countries, this process will identify clear gaps in a
country’s laws and regulatory capacity. Based on this as-
sessment, national leaders should make public and time-
bound commitments to address gaps and to implement
measures that address the most important health chal-
lenges the country is facing. These commitments should
relate to the current political cycle. When introducing and
debating legislation, governments may find it useful torefer to the obligations they owe under international law
to implement the provisions of international agreements
such as the FCTC [14], and to respect, protect and fulfil
the right to health, which – as described above – also
enjoys constitutional protection in many countries [67].
Passing new laws can be difficult, and health leaders
should also consider whether government agencies could
make better use of powers that are already available. For
example, in Australia, the competition and consumer
regulator put an end to the marketing of so-called “light”
and “mild” cigarettes by accepting enforceable undertak-
ings from tobacco manufacturers in exchange for discon-
tinuing court actions against them for misleading and
deceptive conduct under consumer protection legislation
[132]. When passing legislation or making regulations, go-
vernments should ensure that public health officials have a
clear mandate, clear enforcement powers, and adequate
resources for discharging their public health responsibilities.
A second step for governments is to create an enabling
institutional and governance environment to drive ne-
cessary reforms. This includes governance reforms
within the health portfolio, as well as inter-sectoral re-
forms that take account of the interests of different mi-
nistries and create the capacity for a government-wide
response [39,40,133].
Within the health portfolio, countries need – at a mini-
mum – a dedicated tobacco control unit that is free from
interference from the tobacco industry and tobacco
growers, with secure funding, adequate human resources,
enforcement powers, and geographical reach. A number
of countries have successfully introduced health promo-
tion agencies, funded by tobacco taxes, to lead research,
information dissemination, and social marketing efforts
[134]. The WHO has repeatedly emphasised that coun-
tries can achieve sustainable financing for their infrastruc-
ture requirements by raising taxes on tobacco and alcohol
[4,11,54]. Taxes on foods that are high in sugar, salt and
fat, and on sugar-sweetened beverages, may provide
additional revenues [4,135-137].
The priorities for reducing risk factors for NCDs require
the involvement of a range of ministries outside health. In
practical terms, this will require governance structures to
ensure policy coherence and to formalise and maintain a
government-wide commitment. Cross-ministerial execu-
tive committees and taskforces, and cross-government
strategies setting out the contributions expected from each
Ministry towards shared goals, may be useful and should
be adapted to local circumstances. In Mexico, the National
Council for the Prevention and Control of Chronic, Non-
communicable Diseases was established by Presidential
decree. The Council acts as the permanent coordinating
body for national action on NCDs, coordinating actions
among federal government agencies, and between federal
and State governments under the National Health Council
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established the National Prevention Council, which now
comprises heads of 20 federal agencies [139,140]. The
Council was required to develop a national prevention
strategy and to provide annual progress reports on the ac-
tions federal agencies should take to help achieve national
goals for reductions in tobacco use, sedentary behaviour,
and poor nutrition [141].
National responses to HIV provide a useful comparator
for responding to NCDs. In many developing countries,
governments established national AIDS commissions out-
side of the ministry of health in order to bring together
the ministries of health, labour, education, transport, and
justice, and to design and implement national AIDS strat-
egies that engaged all relevant sectors. Similarly, collabor-
ation between international development partners was
facilitated by UN Theme Groups on HIV/AIDS in each
country [142]. These were convened by the UN Resident
Representative and often the chair was rotated among the
participating agencies working in that country. In some
cases their membership was expanded to include non-UN
agencies, government representatives, and leading civil
society organisations, including representatives of people
living with HIV [143].
Accountability for progress in law and
governance reform for NCDs
Global architecture for the response to NCDs continues
to evolve. There have been calls for the development of a
framework convention for the control of alcohol [144],
and of obesity [145], and considerable momentum for a
framework convention on global health to provide a unify-
ing framework for global health efforts [146]. NCDs were
not included in the Millennium Development Goals
(“MDGs”) but have been recognised as a major item on
the agenda for sustainable development and poverty re-
duction [147], and more recently, included in a set of draft
development goals for the post-2015 era [148].
The Political Declaration from the UNGA High-level
Meeting identified the WHO as the international agency
with primary responsibility for leading the global response
to NCDs, in coordination with other UN and international
agencies [80]. The WHO’s primary strategy document is
the Global Action Plan for the Prevention and Control of
Noncommunicable Diseases 2013–2020, adopted by the
World Health Assembly (“WHA”) in May 2013 [149]. As
recommended by the WHA, the United Nations Eco-
nomic and Social Council (“ECOSOC”) has established a
United Nations Task Force on NCDs, co-chaired by
WHO, which will coordinate the activities of UN organisa-
tions and intergovernmental organisations in implement-
ing the Action Plan [149-152]. This Task Force will also
incorporate the work of the United Nations Ad Hoc Inter-
agency Task Force on Tobacco Control [153]. WHO hasprepared a draft division of roles and responsibilities, in
consultation with the Task Force members [154]. Sepa-
rately, the WHA has requested the Director-General to
develop draft terms of reference for a separate “global co-
ordination mechanism” to facilitate engagement among a
wider group of stakeholders including Member States, UN
funds, programmes and agencies, and NGO and private
sector entities, while protecting public health from the
potential for conflicts of interest [155,156].
Key to the success of these global structures will be their
capacity to harness and integrate the energy of civil society
organisations and to create a global movement that influ-
ences the policy agenda at country level. Unlike the Global
Fund [157] and other large global partnerships with for-
malised structures that are organised around the distribu-
tion of funding, the global coordinating mechanisms for
NCDs will not primarily function as funders. Despite their
impact on global health and economic development, there
remains a dramatic disconnect between the impact of
NCDs and the resources available to respond to them: in
2010 only 0.8% of total development assistance in health
(US$18.2 million) was directed to NCDs [81,158]. In the
short term at least, NCDs will need to be addressed pre-
dominantly with domestic funding [159]. At the global
level, economic incentives, legal obligations assumed
under international law, and political commitment (forma-
lised through goals, targets, declarations and partnership
structures) can all help to generate greater momentum for
policy change at the country level [160,161]. It seems clear,
however, that the global process that underpins the emer-
ging architecture for NCDs is largely a political one.
Through formal meetings of member states, consultation
processes and strategic documents, national governments
are being encouraged to provide the funding, to develop
the multisectoral structures, and to make the legislative,
governance and health systems reforms that are required
to fully implement the Global Action Plan.
The comprehensive global monitoring framework,
adopted by the WHA in May 2013, represents one pos-
sible tool for strengthening the commitment of national
governments to prioritise NCDs [162]. Building on the “25
by 25” goal adopted in 2012 [19], the monitoring frame-
work consists of nine voluntary global targets for address-
ing specific behavioural and biological risk factors, and 25
indicators for measuring progress towards each target
[162]. The voluntary targets include a 10% relative reduc-
tion in the harmful use of alcohol, a 30% reduction in
current tobacco use by persons aged 15 years and above, a
30% reduction in mean population salt intake, and a halt
in the rise of obesity. Reports on progress will be submit-
ted to the WHA in 2015, 2020, and finally in 2025 [162].
A striking feature of the monitoring framework is that
it focuses predominantly on monitoring behavioural risk
factors and physiological and epidemiological outcomes,
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evidence-based interventions identified prior to the
UNGA High-level Meeting, and again in the Global Ac-
tion Plan (Table 1). The availability of generic essential
medicines and technologies for NCDs, together with ac-
cess to opioid analgesics, are appropriately included as in-
dicators for the health system's response. Additional
indicators also make reference to vaccination for hepatitis
B and human papilloma virus, eliminating industrially-
produced trans fats from food, and policies to reduce the
marketing of foods high in saturated fats, salt and free
sugars to children. On the other hand, the monitoring
framework imposes no accountability for implementing
WHO’s recommended cost-effective interventions for re-
ducing tobacco use and harmful use of alcohol, and for
improving diets. The risk is that the framework will prove
more useful for its awareness-raising role and capacity to
generate data about the problem, rather than its capacity
to hold countries accountable for implementing the most
powerful solutions. To put it bluntly, what gets measured
gets done: what is not measured is likely to rank as a lower
priority by governments.
In 2013, following the adoption of the Global Action
Plan 2013–2020, WHO initiated a separate consultation
on the indicators to inform on progress in implementing
the action plan [163]. The WHO’s survey instrument for
assessing national capacity and response to NCDs (the
“NCD Country Capacity Survey Tool”), has a greater
focus on policy indicators, including whether or not
countries are implementing taxes on tobacco, alcohol
and foods high in sugar or fat, and whether legislation
has been adopted to regulate food and beverage market-
ing to children, promote breastfeeding, limit trans fats
and reduce salt consumption [164]. However, this instru-
ment is also unlikely to provide adequate data on the full
extent to which policies have been operationalized, in-
cluding through legislation and regulation. It will likely
be left to civil society networks – including, for example,
the recently-announced INFORMAS network for moni-
toring the food environment and obesity – to fill the gap
by documenting the extent to which countries are actually
implementing the laws and policies that can be expected
to reduce NCD risk factors over time [165,166].
The global monitoring and reporting framework [167,168]
that has evolved to monitor implementation of the
Declaration of Commitment made at the 2001 UN
General Assembly Special Session on HIV/AIDS [169],
and subsequent Political Declarations [170], holds im-
portant lessons for NCDs. For example, monitoring
frameworks should include specific legal and policy in-
dicators, rather than being predominantly focused on
changes in epidemiology or access to treatment. Under
the Global AIDS Response Progress Reporting system,
countries are requested to report biennially on progress inimplementing national-level HIV policies, strategies and
laws through the National Commitments and Policy In-
strument [171]. This instrument not only measures pro-
gress in implementing priority laws and policies, but
also enables civil society organisations and development
partners to comment on the rate of progress and what
remains to be done [172].
Priorities for development assistance for NCD law
and governance reform
In earlier sections of the paper we argued that although
progress in preventing and treating NCDs will require the
substantial use of legal and regulatory powers by govern-
ments, there are many obstacles to this, and inadequate
accountability through the global monitoring framework.
At the same time, an analysis of WHO Country Cooper-
ation Strategies in 2012 found that the number of requests
for technical assistance in the area of NCDs exceeded the
number of requests for assistance in health systems
strengthening, and communicable diseases, respectively
[173]. Demand for legal technical assistance is likely to
become increasingly important as countries begin to
seriously consider the most appropriate interventions for
both prevention and treatment. In light of this, what are
the most realistic steps that can be taken to promote the
role of law and to better support NCD-related law reform
at the country level?
Legal and regulatory strategies for the prevention and
treatment of NCDs are not self-executing, but require ad-
herence to the rule of law, and a trained public health
workforce that is resistant to corruption. Investing in pre-
vention means improving institutional capacity to imple-
ment and enforce taxation laws, advertising bans and
other controls on business conduct. It requires an effective
customs service and police force capable of investigating
and prosecuting offences for smuggled and untaxed goods,
such as alcohol and tobacco products. It requires a func-
tioning court system for prosecuting offenders and impo-
sing penalties. In the case of legal and regulatory efforts to
improve diets and to reduce obesity, it requires the ca-
pacity to articulate policy goals and to lead partnerships
with the private sector in ways that strengthen, rather than
undermine, progress towards national health goals. As
these examples illustrate, development assistance to im-
plement priority interventions for NCDs is likely to in-
volve collaboration with a range of ministries, including
health, justice, finance and education.
Given these complexities, we identify three priorities for
the provision of technical assistance to assist countries
with the legal and governance reforms that are needed to
implement the WHO’s Global Action Plan on NCDs
[174]. Firstly, countries need high-quality legal resources
(handbooks, manuals, tool kits) to assist them to evaluate
reform options, taking into account the unique legal
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practice in low- and middle-income countries. Public
health journals routinely call for leadership and policy
change, yet are usually silent about the governance and
law reform processes that are necessary to make these
changes happen. With its unique mandate in public health
law, the WHO has an important opportunity to move be-
yond its two major achievements in public health law –
the FCTC and International Health Regulations – and to
share examples of laws that have been used effectively to
implement its own recommendations for NCD prevention
and treatment [175].
Secondly, investment in capacity-building is urgently
needed to nurture future leaders in public health law, gov-
ernance and advocacy. Training, including the sharing of
experience and technical information, would be especially
useful on a regional basis, between countries that share a
common language, similar legal structure and/or regional
outlook. An understanding of the role of public health law
is important not only for trained lawyers, but for other
leaders in government, Ministry officials, and civil society
representatives. Both of the priorities above will require
funding – remarkably modest funding, in comparison to
the significant sums required for access to NCD treat-
ments. The value of legal assistance in health develop-
ment is poorly understood by donors and development
agencies, despite the significant profile that law and
governance reform has in NCD control, and country re-
quests for assistance. In its absence, it is not surprising
that business interests – including tobacco, alcohol and
food companies – are seeking to fill the policy vacuum
with weak, self-regulatory regimes that impose few con-
straints on their behaviour [176-181].
Thirdly, leadership in public health law is needed at the
global level. Despite its strong constitutional mandate and
comparative advantage as a trusted source of technical ex-
pertise, the WHO currently lacks capacity to discharge this
role effectively. Nevertheless, under the evolving division of
responsibilities between international organisations making
up the UN Interagency Task Force on NCDs, it is likely
that WHO and the United Nations Development Program
(“UNDP”) will be the lead agencies addressing matters re-
lating to law, gender, and human rights [150]. However,
significant opportunities also exist for other organisations
to promote the role of public health law. The World Bank,
regional development banks, large bilateral funders and
other UN agencies can contract legal expertise as required,
yet none appear to have yet recognised the scale of need
that would arise if countries seek to implement the Global
Action Plan in the spirit that advocates are hoping for.
Other organisations, including the International Development
Organization (“IDLO”), the International Parliamentary
Union, and the Commonwealth Secretariat, could also play
a useful role. Academic networks represent an untappedresource, but need to be linked to development agencies
and country needs in a more systematic and productive
way. Important work is being done through the Bloom-
berg Foundation-funded International Legal Consortium
[131], which aims to support tobacco control initiatives in
high-burden countries. The Framework Convention Alli-
ance (the peak civil society organisation supporting the
FCTC) [182] and regional organisations advocate for law
reform, monitor progress, and produce valuable research.
However, the challenge remains for an appropriate agency
or organisation, in partnership with WHO and others, to
assume global leadership in the legal and regulatory
aspects of NCD prevention and control.
Conclusion
This paper has identified priority areas for law reform ad-
dressing the prevention, treatment, and social consequences
of NCDs. The priorities for prevention and treatment of
NCDs, summarised in Tables 1 and 2, illustrate that legal
and regulatory reforms lie at the heart of a successful na-
tional response to NCDs and that law’s role is more sig-
nificant than has been acknowledged. At the same time,
these reforms are not self-executing and will be challen-
ging to achieve, including population-focused measures to
reduce tobacco use, obesity, the over-consumption of al-
cohol, and dietary imbalances. Stricter controls on busi-
ness, in order to align profit-motivated activities more
closely with public health goals, are essential but will be
vigorously contested. Countries will need a robust sense
of their own health sovereignty to implement the reforms
that are needed. The priority for low- and middle-income
countries should be the proven, evidence-informed “best
buys”, that experience already shows will make the most
difference to the burden of disease (Table 1).
Leadership and accountability are vital requirements for
the success of national efforts to prevent and control
NCDs [5]. Globally, the emerging governance structures
rely fundamentally on national governments to assume
leadership and to implement effective laws and policies.
Countries are not being invited to assume legal obligations
under a framework convention, nor is there (yet) any glo-
bal financing mechanism for NCDs. The processes for in-
tegrating the voice of civil society also remain ambiguous.
However, it is these very features that have motivated calls
for a Framework Convention on Global Health to replace
the Millennium Development Goals [146]. The proposed
global monitoring framework for NCDs must be strength-
ened to include comprehensive monitoring, reporting and
accountability for legal and policy action by governments.
The experience of HIV has shown the value of a compre-
hensive, transparent global monitoring framework that
includes indicators for policy, law and human rights.
Global leadership in public health law is currently weak
and fragmented. No global agency combines resources,
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maintains a database of health legislation, but this is neither
complete nor available in electronic format. As Attaran and
colleagues point out, “without reliable sources, good laws
go unnoticed” [175]. Also missing are sources that elaborate
on the history, context and process of passing good and ef-
fective public health laws. The near invisibility of success
stories means that it is more difficult for low- and middle-
income countries and governments to adopt best practice
and to benefit through shared learning. The challenge
remains for development agencies to recognise the
growing need for legal assistance – especially with respect
to NCDs – and to devote more resources to this area.
Appendix A
Constitution of the Republic of South Africa, Section 27:
the right to health care, food, water and social protection
1. Everyone has the right to have access to
a. health care services, including reproductive
health care;
b. sufficient food and water; and
c. social security, including, if they are unable
to support themselves and their dependants,
appropriate social assistance.
2. The state must take reasonable legislative and other
measures, within its available resources, to achieve
the progressive realisation of each of these rights.
3. No one may be refused emergency medical treatment.
The Goals of South Africa’s National Health Act
(Act No. 61 of 2003)
2. Objects of Act
The objects of this Act are to regulate national health
and to provide uniformity in respect of health services
across the nation by:
a) Establishing a national health system which:
i) encompasses public and private providers of
health services; and
ii) provides in an equitable manner the population
of the Republic with the best possible health
services that available resources can afford;
b) Setting out the rights and duties of health care providers,
health workers, health establishments and users; and
c) Protecting, respecting, promoting and fulfilling the
rights of:
i) the people of South Africa to the progressive
realisation of the constitutional right of access
to health care services, including reproductive
health care;
ii) the people of South Africa to an environment
that is not harmful to their health or well-being;iii)children to basic nutrition and basic health care
services contemplated in Section 28(l)(c) of the
Constitution; and
iv) vulnerable groups such as women, children,
older persons and persons with disabilities.Appendix B
Some possible regulatory functions of a national
medicines administration authority [74]
 Establishing a national list of essential medicines
that responds to country-specific needs and disease
burden, with a focus on primary care.
 Establishing evidence-based clinical guidelines for
rational use of prescription medicines.
 Monitoring demand for essential medicines;
monitoring prices in the public and private sectors.
 Educating prescribers and establishing financial
incentives for prescribers to substitute generic brands.
 Preferential registration and quality assurance of
generic medicines.
 Working with donors to reduce duplication of
distribution systems.
 Investigating counterfeit medicines and referring
cases to law enforcement authorities.
 Negotiating prices and licenses on behalf of
government-funded or subsidised health insurance
schemes.
 Monitoring safety and quality of medicines;
investigating safety issues – using legal powers to
inspect premises, to remove, test and recall products,
and to restrain misleading and fraudulent practices.
 Negotiating prices on behalf of government-funded
and -subsidised schemes
 Advising government on use of TRIPS flexibilities.
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